Susceptibility of Bacillus anthracis, Bacillus cereus, Bacillus mycoides, Bacillus pseudomycoides and Bacillus thuringiensis to 24 antimicrobials using Sensititre® automated microbroth dilution and Etest® agar gradient diffusion methods

Journal of Antimicrobial Chemotherapy

Volumn 60, Issue 3, 2007, Pages 555-567

  Luna, Vicki A ^a   King, Debra S ^a   Gulledge, Jenny ^a   Cannons, Andrew C ^a   Amuso, Philip T ^b   Cattani, Jacqueline ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b FLORIDA DEPARTMENT OF HEALTH   (United States)

Author keywords

lactams; Method comparison; Minimum inhibition concentration; Trimethoprim

Indexed keywords

AMPICILLIN; ANTIINFECTIVE AGENT; BETA LACTAM ANTIBIOTIC; CEFTRIAXONE; CHLORAMPHENICOL; CIPROFLOXACIN; CLARITHROMYCIN; CLINDAMYCIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; ERYTHROMYCIN; GATIFLOXACIN; GENTAMICIN; LEVOFLOXACIN; LINEZOLID; MEROPENEM; MOXIFLOXACIN; OXACILLIN; PENICILLIN G; RIFAMPICIN; STREPTOMYCIN; TETRACYCLINE; TIGECYCLINE; VANCOMYCIN;

AGAR GEL DIFFUSION; ANTIBIOTIC SENSITIVITY; ARTICLE; AUTOANALYZER; BACILLUS; BACILLUS ANTHRACIS; BACILLUS CEREUS; BACILLUS MYCOIDES; BACILLUS PSEUDOMYCOIDES; BACILLUS THURINGIENSIS; CONTROLLED STUDY; GENE ISOLATION; INTERMETHOD COMPARISON; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN;

ANTI-BACTERIAL AGENTS; BACILLUS; CULTURE MEDIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; TEMPERATURE; TIME FACTORS;

EID: 34548141841     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkm213     Document Type: Article

References (45)

1. Centers for Disease Control, Prevention. Health Alert Network. Health Update: Inhalation anthrax case investigation, Pennsylvania, New York City - Update, 2/24/06. CDC website: http://www2a.cdc.gov/HAN/ArchiveSys/ ViewMsgV.asp?AlertNum=00242 (7 February 2007, date last accessed).
2. Centers for Disease Control and Prevention. Inhalation anthrax associated with dried animal hides - Pennsylvania and New York City, 2006. MMWR Morb Mortal Wkly Rep 2006; 55: 280-2.
3. Jernigan JA, Raghunathan PL, Bell BP et al. Investigation of bioterrorism-related anthrax, United States, 2001: Epidemiologic findings. Emerg Infect Dis 2002; 8: 1019-28.
4. Clegg S, Wildlife Anthrax Epizootic Workshop Working Group. Preparedness for anthrax epizootics in wildiffe areas [conference summary]. Emerg Infect Dis [serial on the Internet] 2006 July. http://www.cdc.gov/ ncidod/E1D/vol12no07/06-0458.htm (7 February 2007, date last accessed).
5. Rabinowitz P, Gordon A, Chudnov D et al. Animals as sentinels of bioterrorism agents. Emerg Infect Dis 2006; 12: 647-52.
6. Van den Enden E, Van Gompel A, Van Esbroeck M. Cutaneous anthrax Belgian traveler. Emerg Infect Dis 2006; 12: 523-4.
7. Colpin GG, Guiot HFL, Simonis RFA et al. Bacillus cereus meningitis in a patient under gnotobiotic care. Lancet 1981; II 694-5.
8. Craig CP, Lee WS, Ho M. Bacillus cereus endocarditis in an addict. Ann Intern Med 1974; 80: 418-9.
9. Dierick K, Van Coillie E, Swiecicki I et al. Fatal family outbreak of Bacillus cereus-associated food poisoning. J Clin Microbiol 2005; 43: 4277-9.
10. Ghelardi E, Celandroni F, Salvetti S et al. Identification and characterization of toxigenic Bacillus cereus isolates responsible for two food-poisoning outbreaks. FEMS Microbiol Lett 2002; 208 129-34.
11. Ginsburg AS, Salazar LG, True LD et al. Fatal Bacillus cereus sepsis following resolving neutropenic entercolitis during the treatment of acute leukemia. Am J Hematol 2003;72: 204-9.
12. Lund T, De Buyser MI, Granum PE. A new cytotoxin from Bacillus cereus that may cause necrotic enteritis. Mol Microbiol 2005; 38 254-61.
13. Mahler H, Pasi A, Kramer JM et al. Fulminant liver failure in association with the emetic toxin of Bacillus cereus. N Engl J Med 1997; 336: 1142-8.
14. Miller JM, Hair JG, Hebert M et al. Fulminating bacteremia and pneumonia due to Bacillus cereus. J Clin Microbiol 1997; 35: 534-7.
15. Centers for Disease Control and Prevention. Outbreak of cutaneous Bacillus cereus infections among cadets in a university military program - Georgia, August 2004. MMWR Morb Mortal Wkly Rep 2005; 54: 1233-5.
16. Damgaard PH, Granum PE, Bresciani J et al. Characterization of Bacillus thuringiensis isolated from infections in burn wounds. FEMS Immunol Med Microbiol 1997; 18: 47-53.
17. Jackson SG, Goodbrand RB, Ahmed R et al. Bacillus cereus and Bacillus thuringiensis isolated in a gastroenteritis outbreak investigation. Lett Appl Microbiol 1995; 21: 103-5.
18. Ansell SE, Lawton EB, McRae S et al. Endophthalmitis due to Bacillus cereus: Case report. N Z Med J 1980; 92: 12-3.
19. Bast DJ, Athamna A, Duncan CL et al. Type II topoisomerase mutations in Bacillus anthracis associated with high-level fluoroquinolone resistance. J Antimicrob Chemother 2004; 54: 90-4.
20. Brook I, Elliott TB, Pryor HI 2nd et al. In vitro resistance of Bacillus anthracis Steme to doxycycline, macrolides and quinolones. Int J Antimicrob Agents 2001; 18: 559-62.
21. Cavallo JD, Ramisse F, Girardet M et al. Antibiotic susceptibilities of 96 isolates of Bacillus anthracis isolated in France between 1994 and 2000. Antimicrob Agents Chemother 2002; 46: 2307-9.
22. Coker PR, Smith KL, Hugh-Jones ME. Antimicrobial susceptibilities of diverse Bacillus anthracis isolates. Antimicrob Agents Chemother 2002; 46: 3843-5.
23. Drago L, De Vacchi E, Lombardi A et al. Bactericidal activity of levofloxacin, gatifloxacin, penicillin, meropenem and rokitamycin against Bacillus anthracis clinical isolates. J Antimicrob Chemother 2002; 50: 1059-63.
24. Lalitha MK, Thomas M. Penicillin resistance in Bacillus anthracis. Lancet 1997; 349: 1522.
25. Turnbull PCB, Sirianni NM, LeBron CI et al. MiCs of selected antibiotics for Bacillus anthracis, Bacillus cereus, Bacillus thuringiensis and Bacillus mycoides from a range of clinical environmental sources as determined by the Etest. J Clin Microbiol 2004; 42: 3626-34.
26. Athamna A, Athamna M, Abu-Rashed N et al. Selection of Bacillus anthracis isolates resistant to antibiotics. J Antimicrob Chemother 2004; 54: 424-8.
27. Jones ME, Goguen J, Critchley IA et al. Antibiotic susceptibility of isolates of Bacillus anthracis, a bacterial pathogen with the potential to be used in biowarfare. Clin Microbiol Infect 2003; 9: 984-6.
28. Stephenson J. Experts focus on infective agents of bioterrorism. JAMA 2002; 267: 575-6.
29. Weyant RS, Ezzell JW, Popovic T et al. Level B. Laboratory procedure for the identification of Bacillus anthracis. In: Lindsey KQ, Morse SA, eds. Laboratory Protocols for Bioterrorism Response Laboratories for the Identification of Bacillus anthracis. Atlanta, GA: Centers for Disease Control and Prevention, 47-64. 27 June 2005 last revision date. www.cdc.gov (8 February 2DO7, date last accessed).
30. Logan N, Turnbull PCB. Bacillus and other aerobic endospore-forming bacteria. In: Murray PR, Baron EJ, Jorgensen JH et al., eds. Manual of Clinical Microbiology, Eighth Edition. Washington, DC: American Society for Microbiology, 2003; 445-60.
31. Weber DJ, Saviteer SM, Rutala WA et al. In vitro susceptibility of Bacillus spp. to selected antimicrobial agents. Antimicrob Agents Chemother 1988; 32: 642-5.
32. Citron DM, Appleman MD. In vitro activities of daptomycin, ciprofloxacin and other antimicrobial agents against the cells and spores of clinical isolates of Bacillus species. J Clin Microbiol 2006; 44: 3814-8.
33. Jensen LB, Baloda S, Boye M et al. Antimicrobial resistance among Pseudomonas spp. and the Bacillus cereus group isolated from Danish agricultural soil. Environ Int 2001; 26: 581-7.
34. Sengelov G, Agerso Y, Halling-Sorensen B et al. Bacterial anti-biotic resistance levels in Danish farmland as a result of treatment with pig manure slurry. Environ Int 2003; 28: 587-95.
35. Nakamura LK, Jackson MA. Clarification of the taxonomy of Bacillus mycoides. Int J Syst Evol Bacteriol 1995; 45: 46-9.
36. Mohammed MJ, Marston CK, Popovic T et al. Antimicrobial susceptibility testing of Bacillus anthracis: Comparison of results obtained by using the National Committee for Clinical Laboratory Standards broth microdilution reference and Etest agar gradient diffusion methods. J Clin Microbiol 2002;6: 1902-7.
37. Skibicka KP, Tatavarthy A, Luna VA et al. Identification and typing of Bacillus thuringiensis using real-time-PCR, pulsed field gel electrophoresis and riboprinting. In: Abstracts of the One Hundred and Third General Meeting, Washington, DC, 2003. Abstract Y029, p. 669. American Society for Microbiology, Washington, DC, USA.
38. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Sixteenth Informational Supplement M100-S16. CLSI, Wayne, PA, USA, 2006.
39. Clinical and Laboratory Standards Institute. Methods for Antimicrobial Dilution and Disk Susceptibility Testing of Infrequently Isolated or Fastidious Bacteria: Proposed Guideline M45-P. CLSI, Wayne, PA, USA, 2005.
40. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically - Seventh Edition: Approved Standard M7-A7. CLSI, Wayne, PA, USA, 2006.
41. Bakici MZ, Elaldi N, Bakir M et al. Antimicrobial susceptibility of Bacillus anthracis in an endemic area. Scand J Infect Dis 2002; 34: 564-6.
42. Odendaal MW, Pieterson PM, deVos V et al. The antibiotic sensitivity patterns of Bacillus anthracis isolated from the Krueger National Park. Onderstopoort J Vet Res 1991; 58: 17-9.
43. Barrow EW, Bourne PC, Barrow WW. Functional cloning of Bacillus anthracis dihydrofolate-reductase and confirmation of natural resistance to trimethoprim. Antimicrob Agents Chemother 2004; 48: 4643-9.
44. Centers for Disease Control and Prevention. Investigation of bioterrorism-related anthrax and interim guidelines for exposure management and antimicrobial therapy. MMWR Morb Mortal Wkly Rep 2001; 50: 909-19.
45. Lincoln RE, Klein F, Walker JS et al. Successful treatment of rhesus monkeys for septicemic anthrox. Antimicrob Agents Chemother 2006; 4: 759-63.